AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00226941 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)
Study NCT00226941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (HCl)
Description: Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
Study NCT03607578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Protection Routine 2
Description: The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
Study NCT00754533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous versus interval training
Description: Influence of different exercise training programs
Study NCT01182285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
Study NCT00849342 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
Study NCT05423509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic myofascial manipulation
Description: Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
Study NCT05423509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard AIS treatment with observation or bracing
Description: Observation with radiographs and bracing of curves greater than 20 degrees
Study NCT05423509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard AIS treatment with observation or bracing
Description: Observation with radiographs and bracing of curves greater than 20 degrees
Study NCT04204421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM)
Description: Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
Study NCT01172938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Description: Apremilast 20 mg twice daily, orally
Study NCT01172938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30 mg twice daily, orally
Study NCT01172938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 20 mg Apremilast
Description: Placebo + 20 mg Apremilast
Study NCT01172938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 30 mg Apremilast
Description: Placebo + 30 mg Apremilast
Study NCT00917345 — intervention group
Intervention type: DRUG
Intervention: captopril test
Description: The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
Study NCT01332305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn (XP13512/GSK1838262)
Description: Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
Study NCT01332305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily
Study NCT01554046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate- Ritalin IR (Immediate Release)
Description: Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day.
Study NCT01931839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet, oral use
Study NCT01931839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film-coated tablet, oral use
Study NCT05826821 — intervention group
Intervention type: DRUG
Intervention: Pirfenidone
Description: Intervention drug
Study NCT01992536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV
Description: Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine
Study NCT01992536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+¼OMV
Description: Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
Study NCT01992536 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for injection (0.5mL)
Study NCT01182285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
Study NCT01182285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine Sodium
Description: Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
Study NCT00841321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba
Description: 120 mg orally twice a day for 12 weeks
Study NCT00841321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule orally twice a day for 12 weeks
Study NCT01562288 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Study NCT01562288 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT01562288 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Study NCT01562288 — intervention group
Intervention type: OTHER
Intervention: enzyme-linked immunosorbent assay
Study NCT01562288 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT03398161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03398161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03398161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo ultra low dose radiation therapy
Study NCT00248794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)
Description: CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
Study NCT00248794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)
Description: ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
Study NCT00248794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Group (SDG)
Description: Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
Study NCT02632747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin will be taken once daily
Study NCT01717235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride CR Tablets 2mg
Description: Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Study NCT03512340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRF231
Description: SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
Study NCT00979238 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Gene Transfer
Description: Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
Study NCT00979238 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: scAAV2/8-LP1-hFIXco
Description: Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
Study NCT03603405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV/HSV-tk (gene therapy)
Description: The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
Study NCT01398449 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI)
Study NCT02804919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare CPAP Device
Description: Fisher \& Paykel Healthcare CPAP Device
Study NCT03032120 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
Study NCT03032120 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
Study NCT01398449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy only
Study NCT05045521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric warm up group
Description: participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 \* 8 squat jumps, 2 \* 8 scissor jumps, and 2 \* 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos.
Study NCT05045521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance warm up
Description: participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6\*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest
Study NCT05045521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control warm up group
Description: participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6\*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests.
Study NCT02063789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human immunoglobulin intravenous
Description: After GC5107A Intravenous injection, evaluate platelet increase
Study NCT01168050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 400 mg twice per day
Study NCT03659552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIVE Catheter
Description: Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
Study NCT02114892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
Study NCT02114892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
Study NCT01392352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 2 x 400mg pazopanib tablets taken once daily for 12 weeks
Study NCT03127943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Efficacy for mandibular molar and canine anesthesia
Study NCT02855788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
Description: metronomic chemotherapy
Study NCT02632747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matching empagliflozin)
Description: Placebo will be taken once daily
Study NCT01018342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
Study NCT02546752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THEO
Description: THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
Study NCT01018342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrobid® Capsules 100 mg
Study NCT04192786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy program+50 Hz local vibration
Description: Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
Study NCT04192786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy program+100 Hz local vibration
Description: Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
Study NCT04192786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy program
Description: Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
Study NCT00753909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
Study NCT00753909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
Study NCT04098627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: Once weekly 30-minute long group laughter therapy session for 8 weeks
Study NCT00753909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
Study NCT01988493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 300 mg
Description: Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Study NCT01988493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 500 mg
Description: Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Study NCT01988493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 1000 mg
Description: Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
Study NCT01988493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Study NCT01844323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib Formulation Reference
Description: Single 45 mg dose; Dosage form is capsule taken orally.
Study NCT01844323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib Formulation Test
Description: Single 45 mg dose; Dosage form is capsule taken orally.
Study NCT00659269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin (MV)
Description: Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
Study NCT00659269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin + Vitamin B12 + Vitamin B6
Description: Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
Study NCT00659269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800
Study NCT00659269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800
Study NCT01988493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Study NCT02010307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood extraction
Description: 6 ml blood extraction from each patients in all 3 arms of the study
Study NCT00320216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
Study NCT04501341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC
Description: Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10\^5 - 1 x 10\^6 CD34 cells/kgBW
Study NCT04501341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion of UC-MSC
Description: Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10\^6 cells/kgBW, twice, with three months interval
Study NCT00320216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive placebo medication.
Study NCT00320216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients in the placebo group will receive placebo medication.
Study NCT00639158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg capsule, daily, 12 weeks
Study NCT00639158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule, daily, 12 weeks
Study NCT00639158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 40 mg, tablet, daily, 12 weeks
Study NCT00639158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin
Description: 40 mg, tablet, daily, 12 weeks
Study NCT00639158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: 10 mg capsule, daily, 12 weeks
Study NCT00639158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ezetimibe
Description: 10 mg capsule, daily, 12 weeks